Related Experiment Video
Updated: Jan 11, 2026
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
Efficacy and Safety of Mirabegron in Males with Overactive Bladder and Lower Urinary Tract Symptoms: Analysis from an
Farid Abdul Hadi1, Arianne Schild2, Merete Kock Hansen3
1International Markets and China Medical Affairs, Astellas Pharma Singapore Pte. Ltd., Singapore, Singapore.
Background And Objective:
Several phase 2-4 studies have investigated mirabegron for treating patients with overactive bladder (OAB). The objective of this study was to evaluate the efficacy and safety of mirabegron in adult male OAB patients with or without benign prostate enlargement (BPE) receiving medications for lower urinary tract symptoms (LUTS) management.
Methods:
A post hoc analysis of 13 phase 2-4 studies using mirabegron (2- or 4-wk single-blind placebo run-in followed by 12-wk double-blind treatment period) was conducted. The studies had four treatment arms-(1) mirabegron beginning with 25 mg and then escalated to 50 mg (25/50 mg), (2) mirabegron 50 mg, (3) mirabegron 25/50 mg + tamsulosin hydrochloride (HCl) 0.4 mg, and (4) mirabegron 50 mg + tamsulosin HCl 0.2 mg, and three cohorts-cohort 1, OAB males overall; cohort 2, OAB males with concomitant BPE taking alpha blockers; and cohort 3, OAB males with concomitant BPE taking other LUTS medications (not alpha blockers). The primary efficacy endpoints were change from baseline to 12 wk in the mean daily number of micturitions and mean daily number of incontinence episodes. The secondary endpoints included safety, tolerability, and measures of OAB derived from the daily micturition diary, and patient-reported outcomes of voiding and storage.
Key Findings And Limitations:
These results showed improvement in the primary and most secondary endpoints. Participants taking alpha blockers and mirabegron had increased volume voided per micturition. Safety results were consistent with the known profile of mirabegron. Outcomes should be interpreted with caution, as there were few participants taking other LUTS medications.
Conclusions And Clinical Implications:
Results showed that mirabegron is effective and safe in male OAB patients, with or without BPE or receiving medications for LUTS management.
Patient Summary:
We conducted a combined analysis of 13 studies of mirabegron in males with overactive bladder with or without benign prostate enlargement. The analyzed patients included those taking mirabegron and mirabegron combined with other medications for lower urinary tract symptoms. Our results showed that mirabegron was safe and effective in reducing the symptoms of overactive bladder.
Related Concept Videos
01:23Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
01:19Urodynamic Studies: Uroflowmetry
01:30Urinary Tract Calculi III: Medical Management
01:26The Micturition Reflex
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:19Anatomy of the Genitourinary System II: Bladder and Urethra